Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus

References

• Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011 Dec 1;365(22):2110–2121.
   PubMed Web of Science ®Google Scholar
• Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981 Apr;4(4):471–475.
   PubMed Web of Science ®Google Scholar
• Klein R, Moghadam-Kia S, Taylor L, et al. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol. 2011 May;64(5):849–858.
   PubMed Web of Science ®Google Scholar
• Tofighi T, Morand EF, Touma Z. Systemic lupus erythematosus outcome measures for systemic lupus erythematosus clinical trials. Rheum Dis Clin North Am. 2021 Aug;47(3):415–426.
   PubMed Web of Science ®Google Scholar
• Aringer M, Costenbader K, Daikh D, et al. European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019 Sep;71(9):1400–1412. DOI:10.1002/art.40930
   PubMed Web of Science ®Google Scholar
• Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2):288–291.
   PubMed Web of Science ®Google Scholar
• Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993 Jul;86(7):447–458.
   PubMedGoogle Scholar
• Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009 Sep 15;61(9):1143–1151.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014 Jan;73(1):183–190.
   PubMed Web of Science ®Google Scholar
• Loncharich MF, Anderson CW. Interferon inhibition for lupus with anifrolumab: critical appraisal of the evidence leading to FDA approval. ACR Open Rheumatol. 2022 Jun;4(6):486–491.
   PubMedGoogle Scholar
• Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020 Jan 16;382(3):211–221.
   PubMed Web of Science ®Google Scholar
• Bruce IN, Furie RA, Morand EF, et al. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Ann Rheum Dis. 2022 Jul;81(7):962–969.
   PubMed Web of Science ®Google Scholar
• Parodi A, Massone C, Cacciapuoti M, et al. Measuring the activity of the disease in patients with cutaneous lupus erythematosus. Br J Dermatol. 2000 Mar;142(3):457–460.
   PubMed Web of Science ®Google Scholar
• Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677–2686.
   PubMed Web of Science ®Google Scholar
• Durosaro O, Davis MD, Reed KB, et al. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol. 2009 Mar;145(3):249–253.
   PubMedGoogle Scholar
• Izmirly PM, Wan I, Sahl S, et al. The incidence and prevalence of systemic lupus erythematosus in New York County (Manhattan), New York: the manhattan lupus surveillance program. Arthritis Rheumatol. 2017 Oct;69(10):2006–2017.
   PubMed Web of Science ®Google Scholar
• Izmirly PM, Parton H, Wang L, et al. Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the centers for disease control and prevention national lupus registries. Arthritis Rheumatol. 2021 Jun;73(6):991–996.
   PubMed Web of Science ®Google Scholar
• Wieczorek IT, Propert KJ, Okawa J, et al. Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus. JAMA Dermatol. 2014 Mar;150(3):291–296.
   PubMed Web of Science ®Google Scholar
• Grönhagen CM, Gunnarsson I, Svenungsson E, et al. Cutaneous manifestations and serological findings in 260 patients with systemic lupus erythematosus. Lupus. 2010 Sep;19(10):1187–1194. DOI:10.1177/0961203310367656
   PubMed Web of Science ®Google Scholar
• López-Longo FJ, Monteagudo I, González CM, et al. Systemic lupus erythematosus: clinical expression and anti-Ro/SS–a response in patients with and without lesions of subacute cutaneous lupus erythematosus. Lupus. 1997;6(1):32–39. DOI:10.1177/096120339700600105
   PubMed Web of Science ®Google Scholar
• Grönhagen CM, Fored CM, Granath F, et al. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol. 2011 Jun;164(6):1335–1341.
   PubMed Web of Science ®Google Scholar
• Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005 Nov;125(5):889–894.
   PubMed Web of Science ®Google Scholar
• Guidance for IndustryvSystemic lupus erythematosus — developing medical products for treatment. In Services USDoHaH, editor; 2010.
   Google Scholar
• Tiling-Grosse S, Rees J. Assessment of area of involvement in skin disease: a study using schematic figure outlines. Br J Dermatol. 1993 Jan;128(1):69–74.
   PubMed Web of Science ®Google Scholar
• Charman CR, Venn AJ, Williams HC. Measurement of body surface area involvement in atopic eczema: an impossible task? Br J Dermatol. 1999 Jan;140(1):109–111.
   PubMed Web of Science ®Google Scholar
• Charman C, Williams H. Outcome measures of disease severity in atopic eczema. Arch Dermatol. 2000 Jun;136(6):763–769.
   PubMedGoogle Scholar
• Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol. 2009;10(6):365–381.
   PubMed Web of Science ®Google Scholar
• Grönhagen CM, Nyberg F. Cutaneous lupus erythematosus: an update. Indian Dermatol Online J. 2014 Jan;5(1):7–13.
   PubMedGoogle Scholar
• AlE’ed A, Aydin POA, Al Mutairi N, et al. Validation of the cutaneous lupus erythematosus disease area and severity index and pSkindex27 for use in childhood-onset systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000275. DOI:10.1136/lupus-2018-000275
   PubMed Web of Science ®Google Scholar
• Jolly M, Kazmi N, Mikolaitis RA, et al. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures. J Am Acad Dermatol. 2013 Apr;68(4):618–623.
   PubMed Web of Science ®Google Scholar
• Klein R, Moghadam-Kia S, LoMonico J, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011 Feb;147(2):203–208.
   PubMedGoogle Scholar
• Chakka S, Krain RL, Ahmed S, et al. Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus. J Am Acad Dermatol. 2021 Jun;84(6):1562–1567.
   PubMed Web of Science ®Google Scholar
• Kuhn A, Aberer E, Bata-Csörgő Z, et al. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2017 Mar;31(3):389–404.
   PubMed Web of Science ®Google Scholar
• Petri M, Bechtel B, Dennis G, et al. Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel. Lupus. 2014 Sep;23(10):1006–1013.
   PubMed Web of Science ®Google Scholar
• Dubey AK, Handu SS, Dubey S, et al. Belimumab: first targeted biological treatment for systemic lupus erythematosus. J Pharmacol Pharmacother. 2011 Oct;2(4):317–319.
   PubMedGoogle Scholar
• Hui-Yuen JS, Reddy A, Taylor J, et al. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol. 2015 Dec;42(12):2288–2295.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15;61(9):1168–1178.
   PubMed Web of Science ®Google Scholar
• Vashisht P, Borghoff K, O’Dell JR, et al. Belimumab for the treatment of recalcitrant cutaneous lupus. Lupus. 2017 Jul;26(8):857–864.
   PubMed Web of Science ®Google Scholar
• Dresco F, Puzenat E, Delobeau M, et al. Resistant and progressive cutaneous lupus erythematosus treated with belimumab: a retrospective monocentric study. Rev Med Interne. 2020 Mar;41(3):152–159.
   PubMed Web of Science ®Google Scholar
• Okon L, Rosenbach M, Krathen M, et al. Lenalidomide in treatment-refractory cutaneous lupus erythematosus: efficacy and safety in a 52-week trial. J Am Acad Dermatol. 2014 Mar;70(3):583–584.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Werth VP, Furie R, et al. Phase 2 trial of iberdomide in systemic lupus erythematosus. N Engl J Med. 2022 Mar 17;386(11):1034–1045.
   PubMed Web of Science ®Google Scholar
• Cortés-Hernández J, Ávila G, Vilardell-Tarrés M, et al. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther. 2012 Dec 7;14(6):R265. DOI:10.1186/ar4111
   PubMed Web of Science ®Google Scholar
• Furie R, Werth VP, Merola JF, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest. 2019 Mar 1;129(3):1359–1371.
   PubMed Web of Science ®Google Scholar
• Hooks JJ, Moutsopoulos HM, Geis SA, et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979 Jul 5;301(1):5–8.
   PubMed Web of Science ®Google Scholar
• Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2610–2615.
   PubMed Web of Science ®Google Scholar
• Braunstein I, Klein R, Okawa J, et al. The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. Br J Dermatol. 2012 May;166(5):971–975.
   PubMed Web of Science ®Google Scholar
• Pellerin A, Otero K, Czerkowicz JM, et al. Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms. EMBO Mol Med. 2015 Apr;7(4):464–476.
   PubMed Web of Science ®Google Scholar
• Dzionek A, Fuchs A, Schmidt P, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol. 2000 Dec 1;165(11):6037–6046.
   PubMed Web of Science ®Google Scholar
• Cella M, Jarrossay D, Facchetti F, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999 Aug;5(8):919–923.
   PubMed Web of Science ®Google Scholar
• Farkas L, Beiske K, Lund-Johansen F, et al. Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. 2001;159(1):237–243. DOI:10.1016/S0002-9440(10)61689-6
   PubMed Web of Science ®Google Scholar
• Tomasini D, Mentzel T, Hantschke M, et al. Plasmacytoid dendritic cells: an overview of their presence and distribution in different inflammatory skin diseases, with special emphasis on Jessner’s lymphocytic infiltrate of the skin and cutaneous lupus erythematosus. J Cutan Pathol. 2010 Nov;37(11):1132–1139. DOI:10.1111/j.1600-0560.2010.01587.x
   PubMed Web of Science ®Google Scholar
• Furie RA, van Vollenhoven RF, Kalunian K, et al. Trial of Anti-BDCA2 antibody litifilimab for systemic lupus erythematosus. N Engl J Med. 2022 Sep 8;387(10):894–904.
   PubMed Web of Science ®Google Scholar
• Werth VP, Furie RA, Romero-Diaz J, et al. Trial of Anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus. N Engl J Med. 2022;387(4):321–331. DOI:10.1056/NEJMoa2118024
   PubMed Web of Science ®Google Scholar
• Guo LN, Perez-Chada LM, Borucki R, et al. Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need. Lupus Sci Med. 2021 Dec;8(1):e000529.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL, Ardeleanu M, et al. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator’s Global Assessment: a pooled analysis of data from two phase III trials. Br J Dermatol. 2019 Jul;181(1):80–87.
   PubMed Web of Science ®Google Scholar
• Langley RG, Feldman SR, Nyirady J, et al. The 5-point Investigator’s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J DermatolTreat. 2015 Feb;26(1):23–31.
   Google Scholar
• Futamura M, Leshem YA, Thomas KS, et al. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol. 2016 Feb;74(2):288–294.
   PubMed Web of Science ®Google Scholar
• Simpson E, Bissonnette R, Eichenfield LF, et al. The validated investigator global assessment for atopic dermatitis (Viga-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020 Sep;83(3):839–846.
   PubMed Web of Science ®Google Scholar
• Werth VP, Joly P, Mimouni D, et al. Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris. N Engl J Med. 2021 Jun 17;384(24):2295–2305.
   PubMed Web of Science ®Google Scholar
• Werth V, White B, Dgetluck N, et al. Op0162 efficacy and safety of lenabasum in the phase 3 determine trial in dermatomyositis. Annals of the Rheumatic Diseases. 2022;81:106–107.
   Google Scholar
• Patel J, Vazquez T, Chin F, et al. Multidimensional Immune Profiling of Cutaneous Lupus Erythematosus in vivo Stratified by Patient Response to Antimalarials. Arthritis Rheumatol. 2022;74(10):1687–1698.
   PubMed Web of Science ®Google Scholar